Thermo Fisher Scientific and UCSF open cell therapy manufacturing facility
In collaboration with Thermo Fisher Scientific, UCSF has opened a new manufacturing site aimed at accelerating advanced cell and gene therapies for cancer, rare diseases, and other illnesses.
The University of California, San Francisco and Thermo Fisher Scientific have opened a new cGMP manufacturing facility specialising in advanced cell therapies for the treatment of cancer, rare diseases, and other difficult-to-treat illnesses. The facility sits adjacent to the UCSF Medical Center’s Mission Bay campus.
First announced in 2021, the partnership between Thermo Fisher and UCSF will enable scientists, clinicians, and patients closer access to a manufacturing site, and potentially demonstrate how the development of breakthrough treatments may be expedited with increased access to state-of-the-art facilities. The initial focus of the site will be the development of treatments for glioblastomas, multiple myeloma, and other forms of cancer utilising updated approaches on CAR T and CRISPR technologies.
Executive VP and COO of Thermo Fisher Michel Lagarde stated: “Cell therapies represent a rapidly emerging field of biotechnology with tremendous promise for future therapeutic applications. With a record number of cell therapy approvals granted in the last 2 years, and CAR-T therapies becoming earlier treatment options, we’re in a golden age of biology where new technologies and partnerships are evolving and transforming clinical care.”
As part of Thermo Fisher’s global network of pharmaceutical and therapeutic services, including over 15 locations servicing cell and gene therapies, the facility will offer the UCSF community and other customers process and analytical capabilities, and clinical and commercial manufacturing services for advanced cell and gene therapies. Drug development, discovery, and commercialisation will also be accessible for those looking to benefit from Thermo Fisher’s therapeutic development capabilities with this San Francisco facility.
UCSF Chancellor, Sam Hawgood, commented on the site establishment: “UCSF is one of the top clinical sites for CAR-T treatment, and our scientists are leading the next generation of CAR-T therapy development. These approaches will be tested soon in patients with solid tumours like glioblastoma and later in other diseases, including autoimmunity.”
Source: Thermo Fisher Scientific Opens Cell Therapy Facility at University of California, San Francisco, to Accelerate Development of Breakthrough Therapies [Accessed March 27 2023] https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2023/Thermo-Fisher-Scientific-Opens-Cell-Therapy-Facility-at-University-of-California-San-Francisco-to-Accelerate-Development-of-Breakthrough-Therapies/default.aspx
Stay up to date with the latest developments at CPHI Barcelona
Across the industry, businesses large and small are making huge strides forward. At CPHI Barcelona, you can hear from – and meet – representatives from all kinds of pharma enterprises. Find out how they're driving themselves forward and be inspired.
Your CPHI Barcelona pass gives you access to all conference sessions, as well as the chance to connect in-person with the global pharma supply chain from 24-26 October, at Fira Barcelona Gran Via. Browse the agenda and secure your pass today!
Related News
-
News Ardena forms partnership with RiboPro to improve mRNA-based therapies
Ardena and RiboPro have formed an alliance to boost their respective skills in manufacturing and producing nanoparticle and mRNA-based therapeutics to improve accessibility to this technology in the biotherapeutic landscape. -
News Updated: Samsung Biologics to manufacture Pfizer's biosimilars products
Samsung Biologics agrees to use their biocampus Plant 4 for the manufacture of a line of products from Pfizer. -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Soft capsule technology: modified pea starch as a vegetal origin alternative to gelatin in capsule shell
The latest soft capsule technology from Roquette using modified pea starch as an alternative to gelatin. -
News Your Prescription for Marketing Success: Digital Pharma Marketing Toolkit – Free eBook
Download your FREE pharma marketing eBook to learn why it is so important for pharmaceutical marketeers to develop their digital content marketing strategies in order to establish their companies as thought leaders and industry experts. -
News High demand: Vetter expands production capacities and services offered at its Austrian site
Pharma service provider further expands offerings for clinical development and manufacturing -
News Novavax will provide adjuvant Matrix-M for vaccine research with 3-year partnership
Novavax, developers behind the Matrix-M adjuvant, have entered into an agreement with the Bill and Melinda Gates Medical Research Institute to provide the adjuvant in preclinical vaccine research.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance